Cargando…

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

BACKGROUND: Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can further improve treatment efficacy. METHODS: A meta-analysis was performed to evaluate randomized trials c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heinemann, Volker, Boeck, Stefan, Hinke, Axel, Labianca, Roberto, Louvet, Christophe
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292732/ https://www.ncbi.nlm.nih.gov/pubmed/18373843 http://dx.doi.org/10.1186/1471-2407-8-82

Ejemplares similares

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
por: Wilkowski, R, et al.
Publicado: (2009)

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
por: Heinemann, V, et al.
Publicado: (2013)

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
por: Sultana, Asma, et al.
Publicado: (2008)

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy
por: Ormanns, Steffen, et al.
Publicado: (2017)

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
por: Guenther, Michael, et al.
Publicado: (2023)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer
por: Guenther, Michael, et al.
Publicado: (2022)

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2019)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
por: Takada, Ryoji, et al.
Publicado: (2021)

Reply to: The definition of locally advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2010)

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
por: Moon, Do Chang, et al.
Publicado: (2016)

Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Liu, Yanfeng, et al.
Publicado: (2022)

The Spectrum of Pulmonary Toxicity in Pancreatic Cancer Patients Receiving Gemcitabine Combination Chemotherapy
por: Baig, Jalal, et al.
Publicado: (2019)

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult
por: Boeck, S, et al.
Publicado: (2014)

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
por: Cascinu, S, et al.
Publicado: (1999)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

Retracted: Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
por: Hu, Jing, et al.
Publicado: (2011)

Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
por: Liu, Xiaoyu, et al.
Publicado: (2016)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience
por: Pande, Shripad B., et al.
Publicado: (2012)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
por: Chung, Kwang Hyun, et al.
Publicado: (2017)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study
por: Matano, E, et al.
Publicado: (2000)

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
por: de Jesus, Victor H. F., et al.
Publicado: (2020)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2017)

Is gemcitabine (GEM)-based combination therapy good for the treatment of advanced pancreatic cancer?
por: Hao, Fulong, et al.
Publicado: (2023)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C
por: Whitehouse, P A, et al.
Publicado: (2003)

Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rgfqiorp1cku7ec0bg5t3ja745